Takeda appoints Annapurna Das as the General Manager, India Operations

Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines

Biocon posts Q4 FY24 PAT at Rs. 135 Cr

EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%

Elinzanetant significantly reduces frequency and severity of hot flashes associated with menopause

Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms

Cipla invests additional Rs. 26 crore in Achira

Achira is engaged in development and commercialization of PoC medical test kits in India

Granules India posts Q4 FY24 consolidated PAT at Rs. 129.64 Cr

The company has posted net profit of Rs. 405.31 crores for the Financial Year ended March 31, 2024

Ind-Swift posts Q4 FY24 consolidated PAT at Rs. 37.53 Cr

The company has posted net profit of Rs. 14.23 crores for the Financial Year ended March 31, 2024

Bayer starts Phase I study with novel targeted radionuclide therapy in advanced metastatic prostate cancer

225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer

IOL Chemicals and Pharmaceuticals posts Q4 FY24 consolidated PAT at Rs. 27.62 Cr

The company has posted net profit of Rs.134.43 crores for the Financial Year ended March 31, 2024

Thyrocare Technologies posts Q4 FY24 consolidated PAT at Rs. 17.78 Cr

The company has posted net profit of Rs.70.76 crores for the Financial Year ended March 31, 2024

Biocon signs supply deal with Medix for commercialization of generic Saxenda in Mexico